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CC BY-NC-ND license (http://creativeAbstract Objective: To obtain a formulation with high bioavailability through evaluation of
the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats. We
compared the stability of the Panax notoginsenoside R1 as well as the ginsenosides Rg1, Rb1,
Re, and Rd in different formulations.
Methods: Artificial stomach fluid (ASF) and artificial intestinal fluid (AIF) were prepared. Sta-
bility of three types of Xuesaitong capsules was examined for 4 h in stomachs and 24 h in in-
testines. Samples were analyzed at different times by high-performance liquid
chromatography. Percent content of NGR1, GRg1, GRb1, GRe, and GRd at different times
was calculated.
Results: Hard capsules incubated in ASF disintegrated within 2e3 min, whereas soft cap-
sules disintegrated within 7e8 min. Components in hard capsules were dissolved rapidly
in water, with content of each compound reaching 90% in 5 min, and degradation of each
compound reaching 30e50% after incubation for 240 min. Dissolution and degradation of
each component in soft capsules with a water-soluble base tended to balance at 30
e90 min. Contents in soft capsules with a lipid-soluble base showed slow dissolution after
ASF incubation for 120 min. Five saponins in identical types of capsules incubated in ASF
had similar stability curves. Contents of hard capsules and soft capsules with a water-
soluble base degraded rapidly within 30 min and reached a plateau when Xuesaitong cap-
sules were incubated in AIF.86 10 8473 8615.
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42 B. Yang et al.Table 1 Gradients of the mobile
Time (min) Phase A (%, acetonit
0 19
25 19/ 45
50 45/ 55
55 55/ 19
60e70 19Conclusions: Contents of capsules with a lipid-soluble base degraded slower than the other
two types of capsules incubated in ASF and AIF, suggesting that they may have better
bioavailability.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Xuesaitong is a traditional Chinese herbal formula in
capsule form used to promote blood circulation and
dilate blood vessels. As such, in China, the formula is
used for the treatment of coronary heart disease, angina,
stroke, paralysis and other cardiovascular/cerebrovas-
cular diseases. Studies have shown that Xuesaitong cap-
sules can reduce platelet aggregation, increase blood
flow, improve hemodynamics,1 improve neurologic defi-
ciency2,3 and improve symptoms of coronary heart dis-
ease and angina.4
Main active components of Xuesaitong formula are Panax
notoginseng saponins (PNS). Protopanaxatriol-type sapo-
nins such as NGR1, GRg1, and GRe can be metabolized to
protopanaxatriol, which is absorbed into blood via oral
administration. Our previous studies showed differences in
peak blood concentrations of protopanaxatriol for three
types of Xuesaitong capsules after oral administration in
beagle dogs. Protopanaxadiol-type saponins GRb1 and GRd
were absorbed poorly through oral administration,5 and the
absolute bioavailability of GRb1 was only 0.26%. Oral dosage
forms of PNS can be metabolized by enzymes and intestinal
flora.
We examined the stability of three types of Xuesaitong
capsules incubated in the stomachs and intestines of rats.
We compared the stability of NGR1, GRg1, GRb1, GRe, and
GRd in different formulations to obtain a formulation with
high bioavailability.Table 2 Linear relationship between NGR1, GRg1, GRb1,Materials and methods
Materials
The PNS R1, the ginsenosides Rg1, GRg1, Rb1, Re, and Rd,
and standards were obtained from the National Institute for
the Control of Pharmaceutical and Biological Products
(Beijing, China). Sodium chloride was purchased from Bei-
jing Chemical Reagents (Beijing, China). Pepsase andphase.
rile) Phase B (%, water)
81
81/ 55
55/ 45
45/ 81
81trypsase were obtained from Cytoskeleton (Denver, CO,
USA). High-performance liquid chromatography (HPLC)-
grade acetonitrile was from MREDA Technology (Beijing,
China). Ultrapure water was generated from a Synergy ul-
traviolet water-purification system (Millipore, Billerica, MA,
USA). Xuesaitong capsules (batch number: 20111023) were
obtained from Yunnan Weihe Pharmaceuticals (Yunnan,
China). Xuesaitong soft capsules (batch number: 20121017
163) were purchased from Kunming Flame Pharmaceuticals
(Kunming, China), as were Xuesaitong soft capsules with a
batch number of 13109-10.Animals
Male SpragueeDawley rats (220e250 g) were purchased
from Vital River Laboratories (Beijing, China). Rats were
fasted for 24 h but had unlimited access to water before
experimentation.
Animal experiments were undertaken in accordance
with the Guidelines for the Care and Use of Laboratory
Animals (US National Institutes of Health, Bethesda, MD,
USA). The study protocol was approved by the Animal
Experimentation Committee of the Beijing University of
Chinese Medicine (Beijing, China).Method validation
HPLC conditions
PNS were analyzed by HPLC using a Extend-C18 column
(4.6 mm 250 mm, 5 mm; Agilent Technologies, Santa Clara,
CA, USA) and a pre-column (WATCH Y164; Agilent Technolo-
gies) with ultraviolet detection (l Z 203 nm). The mobile
phase was acetonitrile and water and eluted according to
values shown in Table 1. The mobile phase was pumped at
1.5 mL/min at 37C, and the injection volume was 20 mL.GRe and GRd (n Z 6).
Constituent Regression
equation
r Linearity
range
(mg/L)
NGR1 Y Z 2.2789X  9.4934 0.9999 5.2e104.0
GRg1 Y Z 2.5522X  21.7050 0.9999 12.5e250.0
GRe Y Z 2.2698X  6.8187 0.9999 2.2e44.0
GRb1 Y Z 1.8148X  9.3990 0.9999 11.9e238.0
GRd Y Z 2.2023X  1.2172 0.9999 2.6e52.0
Table 3 Drug accumulation at different times in artificial stomach fluid (soft capsule with a lipid-soluble base) (n Z 6).
Time (min) NGR1 GRg1 GRe GRb1 GRd
3 0 0 0 0 0
10 0.51  0.32 2.47  1.58 0.07  0.02 1.19  0.51 0.14  0.10
15 0.75  0.59 2.88  1.81 0.17  0.08 1.79  1.08 0.38  0.22
30 2.05  0.27 8.77  1.45 0.84  0.20 5.58  1.09 1.30  0.37
60 3.02  0.08 13.37  0.48 1.34  0.21 9.63  0.41 2.88  0.25
90 3.37  0.22 14.65  0.31 1.41  0.18 11.55  0.34 3.85  0.09
120 3.31  0.26 14.44  0.61 1.30  0.17 12.20  0.66 4.24  0.37
240 2.42  0.22 10.75  0.42 1.01  0.21 10.93  0.57 4.31  0.18
Table 4 Drug accumulation at different times in artificial stomach fluid (soft capsule with a water-soluble base) (n Z 6).
Time (min) NGR1 GRg1 GRe GRb1 GRd
3 0 0 0 0 0
10 0.61  0.23 2.15  0.76 0.26  0.11 1.73  0.86 0.39  0.23
15 1.88  0.61 7.87  2.50 1.33  0.79 8.70  3.32 1.76  0.68
30 3.64  0.57 12.56  0.78 1.70  0.58 15.04  1.27 3.58  0.34
60 2.94  0.55 10.66  0.81 1.52  0.26 14.64  0.96 3.65  0.34
90 2.65  0.48 8.77  0.80 1.15  0.22 13.22  0.51 3.50  0.13
120 1.04  0.11 4.07  0.39 0.52  0.07 6.72  0.52 1.82  0.07
240 0.75  0.20 2.43  0.24 0.35  0.04 5.67  0.74 1.40  0.68
Table 5 Drug accumulation at different times in artificial stomach fluid (hard capsule) (n Z 6).
Time (min) NGR1 GRg1 GRe GRb1 GRd
1 0 0 0 0 0
5 5.21  1.80 29.02  9.80 3.71  1.33 19.57  8.87 5.00  2.82
15 4.61  0.25 26.07  1.44 3.26  0.27 16.30  1.30 4.35  0.60
30 4.07  0.22 22.98  1.10 2.83  0.22 13.80  0.80 3.57  0.37
60 3.55  0.15 20.30  0.82 2.53  0.19 13.41  0.55 3.79  0.15
90 2.99  0.10 17.08  0.58 2.00  0.19 12.34  0.36 3.88  0.23
120 2.76  0.22 15.90  1.19 1.93  0.27 12.31  1.08 3.97  0.30
240 1.70  0.13 9.72  0.54 1.16  0.06 9.19  0.33 3.65  0.26
Table 6 Drug accumulation at different times in artificial intestinal fluid (soft capsule with a lipid-soluble base) (n Z 6).
Time (h) Panax notoginsenoside R1 Ginsenoside Rg1 Ginsenoside Re Ginsenoside Rb1 Ginsenoside Rd
0.08 2.01  0.26 7.92  0.78 0.62  0.12 6.12  0.86 1.09  0.28
0.25 1.91  0.24 7.03  0.71 0.58  0.12 6.87  0.83 1.67  0.34
0.50 2.21  0.21 9.15  0.97 0.64  0.08 8.74  1.36 2.72  0.65
1.00 2.64  0.42 10.18  1.41 0.73  0.18 10.93  2.26 3.68  1.22
1.50 2.74  0.30 10.87  0.67 0.74  0.10 13.12  3.51 4.87  1.83
2.00 2.89  0.24 11.51  0.61 0.81  0.12 15.50  3.92 5.90  2.16
4.00 3.00  0.26 12.05  0.91 0.86  0.14 16.20  2.94 6.25  1.67
6.00 3.68  0.72 14.73  3.12 0.92  0.18 18.96  4.85 7.67  2.64
8.00 3.46  0.39 13.72  1.19 0.92  0.13 19.23  6.25 7.40  3.31
12.00 3.44  0.30 13.77  0.53 0.95  0.10 15.76  5.24 5.59  2.70
18.00 3.85  0.65 14.97  1.56 1.13  0.16 15.38  1.78 4.95  0.69
24.00 3.91  0.25 15.05  0.95 1.07  0.17 16.42  2.49 5.54  1.47
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Figure 1 Percent content of each component of hard and
soft capsules at different times in artificial stomach fluid. A:
Soft capsule with a lipid-soluble base; B: Soft capsule with a
water-soluble base; C: Hard capsule.
44 B. Yang et al.Configuration of hybrid standards
Stock standard solutions of hybrid standards were prepared
by dissolving the accurately weighed standard compound in
methanol to a final concentration (mg/L) of 0.203 for NGR1,
0.822 for GRg1, 0.112 for GRb1, 0.872 for GRe, and 0.214 for
GRd.
Linearity
The mixed standard solution was diluted to six concentra-
tions. The standard solution was used according to thechromatographic conditions shown in section 2.2.1 and
20 mL injected. Linear regression by peak area (Y) of the
mass concentration of the sample (mg/L) was obtained.
The regression equation of each component is shown in
Table 2.
Precision and accuracy
Intra-day precision and accuracy of the method were
determined by analyzing six replicates at a specific con-
centration and a relative standard deviation <3%.Stability of capsules in rat stomachs
Preparation of a solution of rat stomach contents
Rats were fasted for 24 h but had unlimited access to
water before experimentation. Rats were narcotized
with 20% ethyl carbamate. A small incision (3 cm) was
made in the abdomen. A small incision was made in the
bottom of the stomach. A silicone tube was inserted and
fixed. The stomach was lavaged with 15 mL of artificial
gastric fluid (dilute hydrochloric acid, 8.2 mL; 400 mL of
water; pepsin, 5 g) at 37C using a syringe. The effluent
was collected and water added to make up to 500 mL.
This procedure was repeated five times. Three lavages of
rat-stomach contents were collected together
(z45 mL), and artificial gastric fluid added to make up
to 50 mL.
Incubation of artificial stomach fluid
Two grams of soft capsules with a lipid-soluble base, 1 g of
soft capsules with a water-soluble base, and 1 g of hard
capsule were added in three conical flasks. The solution of
rat stomach contents (50 mL) was added to each flask and
incubated in a 37C shaking incubator at 150 rpm. Aliquots
(1 mL) were taken at 1, 5, 15, 30, 60, 90, 120, and 240 min
for hard capsules, and at 3, 10, 15, 30, 60, 90, 120, and
240 min for soft capsules. The same volume of a fresh, pre-
warmed solution of artificial stomach fluid was added to
keep the volume constant. The disintegration time was
recorded. To each sample was added 450 mL NaOH
(0.1 mol/mL) to neutralize gastric acid and terminate the
reaction. Supernatants were analyzed for content by
HPLC.Stability of capsules in intestines
Preparation of artificial intestinal fluid
Rats were fasted for 24 h but had unlimited access to water
before experimentation. Rats were anesthetized with 20%
ethyl carbamate. A small incision (3 cm) was made in the
abdomen. A small incision was made in the bottom of the
ileum. A silicone tube was inserted and fixed. Intestines
were lavaged with 40 mL artificial intestinal fluid (monop-
otassium phosphate, 6.8 g; 500 mL water; adjust the pH to
6.8 with 0.1 mol/L sodium; pancreatic enzymes, 5 g) at
37C using a syringe. The effluent was collected and water
added to make up to 1 L. This procedure was repeated five
times. Three lavages of rat-intestine contents were
collected together (w45 mL) and artificial intestinal fluid
added to make up to 50 mL.
Table 7 Drug accumulation at different times in artificial intestinal fluid (soft capsule with a water-soluble base) (n Z 6).
Time (h) Panax notoginsenoside R1 Ginsenoside Rg1 Ginsenoside Re Ginsenoside Rb1 Ginsenoside Rd
0.08 5.84  0.21 19.39  0.52 2.29  0.33 15.34  0.44 3.27  0.32
0.25 3.48  0.18 11.46  0.41 1.65  0.29 9.39  0.27 2.14  0.21
0.50 3.14  0.07 10.31  0.18 1.38  0.21 8.35  0.24 1.92  0.19
1.00 3.34  0.32 11.06  0.89 1.49  0.12 8.71  0.25 1.93  0.19
1.50 3.88  0.13 12.79  0.33 1.65  0.10 9.81  0.28 2.13  0.21
2.00 3.60  0.14 11.79  0.22 1.62  0.10 8.68  0.25 1.59  0.16
4.00 4.14  0.68 13.52  2.07 1.83  0.26 10.14  0.29 2.17  0.21
6.00 3.96  0.38 13.02  1.08 1.87  0.21 10.16  0.29 2.16  0.21
8.00 3.55  0.34 11.71  1.03 1.63  0.20 8.59  0.25 1.74  0.17
12.00 3.80  0.38 12.58  1.33 1.77  0.27 10.10  0.29 2.34  0.23
18.00 3.72  0.11 12.20  0.23 1.69  0.10 9.58  0.28 2.21  0.22
24.00 3.97  0.40 13.04  1.31 1.85  0.16 10.44  0.30 2.42  0.24
Stability of Xuesaitong capsules 45Incubation in artificial intestinal fluid
Two grams of soft capsules with a lipid-soluble base, 1 g of
soft capsules with a water-soluble base, and 1 g of hard
capsules were added to three conical flasks. Rat intestinal
contents (50 mL) were added to each flask followed by in-
cubation in a 37C shaking incubator at 150 rpm. Aliquots
(1 mL) were taken at 5, 15, 30, 60, 90, 120, 240, 360, 480,
720, 1080, and 1440 min. An identical volume of fresh, pre-
warmed solution of artificial intestinal fluid was added to
keep the volume constant. Supernatants were analyzed for
content by HPLC.
Data and statistical analyses
Drug accumulation in the solution of rat-stomach contents
was calculated using Eq. (1).
QnZ1:45 50Cn þ
Xn1
iZ1
Ci  1:45 1 ð1Þ
where Qn is the drug accumulation, Cn is the concentration
of n point (mg/mL),Ci is the concentration of the i point
(I  n  1).
Drug accumulation in the solution of rat intestinal con-
tents was calculated using Eq. (2).
QnZ1 50Cnþ
Xn1
iZ1
Ci  1 ð2Þ
where Qn is the drug accumulation, Cn is the concentration
of the n point (mg/mL) and Ci is the concentration of the i
point (I  n  1).
Results
We chose different times of sampling because of the time
soft capsules and hard capsules rupture. In the solution of
rat stomach contents, hard capsules disintegrated rapidly
and ingredients were dissolved in 2e3 min, whereas the
two types of soft capsules disintegrated at 7e8 min (Table
3).PNSs have poor stability in acid media and degrade
rapidly.5 In artificial stomach fluid, in the three types of
capsules, contents of five saponins increased initially
and then decreased, thereby embodying dis-
solutionedegradation (Tables 4e6). Soft capsules with a
lipid-soluble base dissolved slowly, the contents of five
saponins reached a maximum at 60 min, and then a bal-
ance in the dissolution and degradation of each compo-
nent was reached (Table 4). After soft capsules with a
water-soluble base disintegrated, dissolution of the con-
tents of five saponins reached a maximum at 30 min; after
120 min, degradation of each component reached a
plateau. Hard capsules disintegrated rapidly, dissolution
of each component reached a maximum at 5 min, and
then each component was degraded in artificial stomach
fluid.
Contents of five saponins in identical capsules had
similar stability curves in artificial stomach fluid (Fig. 1).
Various components of hard capsules were degraded after
rapid dissolution, and percent content of the ginsenoside
Re reached 90% at 5 min. Because of gastric acid and
related enzymes, the reaction rate of each compound was
different, which caused differences in the degradation of
each compound. The ginsenoside Rd degraded most slowly,
followed by the ginsenoside Rb1. The five saponin constit-
uents in the soft capsule with a lipid-soluble base dissolved
slowly and percent content increased slowly over time,
taking 120 min to reach a plateau. Each constituent of the
soft capsule with a water-soluble base showed dissolution
at 30 min, and dissolutionedegradation reached a balance
at 30e60 min (Table 7).
When the three types of capsules were incubated in
artificial stomach fluid, the percent content of five sa-
ponins in hard capsules were higher than those in soft
capsules with a water-soluble base and soft capsules with
a lipid-soluble base at 60 min. The content of each
component in hard capsules and soft capsules with a lipid-
soluble base had similar percent content after 240 min of
incubation. Compared with hard capsules, soft capsules
disintegrated more slowly. Because of the lipid-soluble
base, each component dissolved slower than soft capsules
Figure 2 Comparison of the percent content of five saponin constituents in hard and soft capsules at different times. A: Panax
notoginsenoside R1; B: Ginsenoside Rg1; C: Ginsenoside Re; D: Ginsenoside Rb1; E: Ginsenoside Rd.
46 B. Yang et al.with a water-soluble base, and the lipid base tended to
float on the upper part of the fluid (which reduced the
content of all compounds in artificial stomach fluid)
(Fig. 2).
Just like capsules incubated in artificial stomach fluid,
PNS were degraded in artificial intestinal fluid because of
enzymes. Contents of hard and soft capsules with a lipid-
soluble base incubated in artificial intestinal fluid led to
rapid degradation of PNS at 30 min, with each component
showing a linear decrease. Contents of soft capsules with alipid-soluble base incubated in artificial intestinal fluid
decreased after an initial increase before reaching a
plateau.
Contents of hard and soft capsules with a water-soluble
base dissolved rapidly in the solution of rat intestinal con-
tents and then degraded quickly. Because of intestinal
enzymes, the reaction rate of each compound differed,
which led to differences in the degradation of each
component, but all reached a plateau at w30 min. Con-
tents of soft capsules with a lipid-soluble base tended to
Figure 3 Percent content of each component of hard and
soft capsules at different times in artificial intestinal fluid.
A: Soft capsule with a lipid-soluble base; B: Soft capsule with a
water-soluble base; C: Hard capsule.
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contents. This phenomenon reduced the dissolution rate of
all compounds, and all components were dissolved
completely at 6 h and then showed degradation (Fig. 3).
Constituents of five saponins in identical capsules had
similar metabolism after 24 h of incubation in the solution
of rat intestinal contents. Compounds in soft capsules with
a lipid-soluble base were suspended in the oil phase and
dissolved slowly.Degradation curves of five saponins in hard and soft
capsules with a water-soluble base incubated in
the solution of artificial intestinal fluid were similar (Fig. 4).
Percent content of ginsenoside Rb1 and ginsenoside Rd of
soft capsules with a lipid-soluble base was higher than that
of hard and soft capsules with a water-soluble base when
incubated for 60 min. Percent content of Panax noto-
ginsenoside R1, ginsenoside Rg1 and ginsenoside Re was
basically identical when the three types of capsules were
incubated in artificial intestinal fluid for 24 h.Discussion
We examined the stability of Panax notoginsenoside R1 as
well as the ginsenosides Rg1, Re, Rb1 and Rd in three types
of Xuesaitong capsules incubated in artificial stomach fluid
and artificial intestinal fluid.
Five types of saponins in three types of capsules
incubated in artificial stomach fluid manifested dissolu-
tion and degradation. Hard capsules disintegrated faster,
with rapid dissolution of components followed by degra-
dation. Soft capsules with a water-soluble base dis-
integrated atz7e8 min, and dissolution and degradation
reached a balance at 30e90 min. Compounds in soft
capsules with a lipid-soluble base dispersed in the oil
phase and dissolved slowly. Each compound tended to
reach a plateau after 120 min of incubation. When
incubated in the solution of artificial intestinal fluid,
contents of hard and soft capsules with a water-soluble
base were degraded rapidly. Compounds of soft cap-
sules with a lipid-soluble base dissolved slowly and then
degraded (Table 8).
In the human body, secretion of gastric juice, intestinal
juice, and enzymes occurs. Hard capsules and soft capsules
with a water-soluble base in the stomach were affected
mainly by changes in levels of gastric acid and enzymes.
Degradation in the intestines is influenced mainly by
enzyme secretion.
Compounds in soft capsules with a lipid-soluble base
were affected less by digestive juices, so degradation was
lower than that observed in hard and soft capsules with a
water-soluble base. In vivo experiments have shown that
PNS have poor bioavailability.6 Also, levels of ginsenosides
measured in Caco-2 monolayers have suggested that the
membrane permeability of most ginsenosides is poor, with
Papp values <3  106.7 A possible mechanism may be that
PNS have low compatibility with cell membranes. Oil-phase
matrices are more likely to promote drug absorption, so
soft capsules with a lipid-soluble base may have higher
bioavailability.
PNS are the main components of Xuesaitong capsules.
The latter have various pharmacologic effects, including
anti-thrombus formation, promotion of the growth of he-
matopoietic cells, circulation of cerebral blood flow, and
myocardial protection.8,9 PNS R1 as well as ginsenosides
Rg1, Re, Rb1, and Rd account for z80% of PNS.
10 It has
been reported that notoginseng saponin R1, ginsenoside
Rg1 and ginsenoside Rb1 are unstable in acid media. We
also found that PNS were degraded in the solution of
artificial stomach fluid, a finding that is in accordance
with other reports.11
Figure 4 Comparison of percent content of five saponin constituents in hard and soft capsules at different times. A: Panax
notoginsenoside R1; B: Ginsenoside Rg1; C: Ginsenoside Re; D: Ginsenoside Rb1; E: Ginsenoside Rd.
48 B. Yang et al.The greatest difference was in the incubation of hard
capsules. Because of the oil-phase matrix, each compound
in a soft capsule with a lipid-soluble base reached a dis-
solutionedegradation balance after 90 min, and percent
content remained unchanged during incubation in artifi-
cial stomach fluid. All five saponins incubated in the so-
lution of artificial intestinal fluid were degraded, andwere affected mainly by enzymes and intestinal flora. The
oil-phase matrix of soft capsules with a lipid-soluble base
could avoid degradation to a certain degree, thereby
showing a sustained-release effect. In summary,
compared with hard and soft capsules with a water-
soluble base, soft capsules with a lipid-soluble base had
better bioavailability.
Table 8 Drug accumulation at different times in artificial intestinal fluid (hard capsules) (n Z 6).
Time (h) Panax notoginsenoside R1 Ginsenoside Rg1 Ginsenoside Re Ginsenoside Rb1 Ginsenoside Rd
0.08 6.89  0.26 37.26  1.85 2.72  0.82 17.94  4.18 3.58  1.24
0.25 4.63  0.44 25.19  1.64 1.82  0.31 13.14  1.01 2.63  0.27
0.50 4.18  0.14 22.67  0.79 1.65  0.40 9.42  0.87 1.49  0.27
1.00 4.16  0.17 22.74  1.00 1.74  0.30 7.88  0.42 1.02  0.13
1.50 4.13  0.22 22.77  1.12 1.72  0.36 7.59  0.39 0.97  0.15
2.00 4.16  0.14 23.06  0.97 1.72  0.29 7.32  0.43 0.89  0.14
4.00 4.16  0.15 23.04  0.87 1.72  0.28 7.57  0.30 0.90  0.07
6.00 4.41  0.25 24.58  1.35 1.82  0.31 8.17  0.74 1.09  0.25
8.00 4.29  0.20 23.85  0.90 1.76  0.26 8.11  0.62 1.07  0.21
12.00 4.40  0.19 24.03  1.12 1.85  0.27 8.83  0.52 1.23  0.18
18.00 4.67  0.18 24.75  1.21 1.83  0.30 12.46  0.83 2.48  0.29
24.00 4.44  0.10 23.58  0.90 1.71  0.31 11.60  0.61 2.29  0.28
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